NYSE:MUX
NYSE:MUXMetals and Mining

McEwen’s Grey Fox Resource Growth And Mine Plan Versus Recent Rally

McEwen (NYSE:MUX) reported a 23% year over year increase in Indicated gold resources at its Grey Fox Project. The company plans to fold recent property acquisitions, including the Stroud Property, into the next phase of Grey Fox development. New high grade drill results and an accelerated underground mining approach are set to inform the updated project plan. For investors tracking McEwen, the Grey Fox update comes on the heels of a sharp share price move, with NYSE:MUX up 17.3% over the...
NYSE:VMI
NYSE:VMIConstruction

A Look At Valmont Industries (VMI) Valuation After Recent Share Price Momentum And Modest Pullback

What Just Happened With Valmont Industries (VMI)? Valmont Industries (VMI) has been drawing fresh attention after its recent share price performance, with the stock showing mixed short term moves but positive returns over the past month and past 3 months. See our latest analysis for Valmont Industries. At around $440 per share, Valmont Industries has seen a modest pullback in the last week, while its 1 month and year to date share price returns remain positive and its 1 year total...
OTCPK:SKYC
OTCPK:SKYCCapital Markets

Sky Constant Century (OTCPK:SKYC) Valuation Check After Board Refresh And Recent Share Price Surge

Sky Constant Century (SKYC) has recently reshaped its board by adding Mr. Zhiqing Lu and Mr. Huibin Jiang. The company links these appointments to sharpening governance as it assesses future business opportunities and potential new directions. See our latest analysis for Sky Constant Century. The recent board changes come as the share price has moved sharply, with a 1 day share price return of 58.56% and a very large 90 day share price return. However, the 3 year and 5 year total shareholder...
NasdaqGS:PDD
NasdaqGS:PDDMultiline Retail

Regulatory Clash Puts PDD Holdings Governance And Growth Story Under Scrutiny

Chinese regulators have escalated their investigation into PDD Holdings (NasdaqGS:PDD), sending more than 100 investigators to the company’s headquarters. The probe focuses on alleged fraudulent deliveries and tax compliance issues, following a physical altercation between PDD employees and officials. Authorities have issued fines, PDD has dismissed staff involved in the incident, and operations have experienced delays in marketing and project timelines. Multiple law firms have launched...
NYSE:AIZ
NYSE:AIZInsurance

Is Assurant (AIZ) Still Attractive After Strong Multi Year Share Price Gains?

If you are wondering whether Assurant at around US$233 per share still offers value, you are not alone. The stock’s current price invites a closer look at what you are actually paying for. The share price closed at US$233.39, with returns of a 0.3% decline over 7 days, a 3.5% decline over 30 days and a 1.8% decline year to date, while the 1 year and 3 year returns stand at 12.4% and 88.5% respectively, and the 5 year return is 87.9%. Recent price moves sit against a backdrop of ongoing...
NasdaqGS:PLTR
NasdaqGS:PLTRSoftware

Palantir Technologies (PLTR) Valuation Check After New HD Hyundai Alliance And Sovereign AI Wins

Palantir Technologies (PLTR) is back in focus after two major commercial wins: an expanded multi year alliance with HD Hyundai in Korea and a role in new sovereign AI data centers across EMEA, ahead of its upcoming earnings. See our latest analysis for Palantir Technologies. Despite the HD Hyundai expansion and the new sovereign AI role, Palantir's 30 day share price return of 12.65% and 90 day share price return of 8.14% indicate fading near term momentum. At the same time, the 1 year total...
NasdaqCM:ESTA
NasdaqCM:ESTAMedical Equipment

Did Rising U.S. Motiva Revenue in Q4 2025 Just Shift Establishment Labs' (ESTA) Investment Narrative?

In January 2026, Establishment Labs Holdings Inc. reported preliminary unaudited revenue guidance for the fourth quarter of 2025 of US$64.0 million to US$65.0 million, including US$17.0 million to US$17.5 million from Motiva sales in the United States. For full-year 2025, the company expects US$210.5 million to US$211.5 million in revenue, with Motiva’s United States contribution highlighting the growing importance of that market within its overall sales mix. We’ll examine how this...
NasdaqGS:COCO
NasdaqGS:COCOBeverage

Assessing Vita Coco (COCO) Valuation After Strong Multi‑Year Returns And Rich P/E Multiple

Recent performance snapshot Vita Coco Company (COCO) has drawn fresh attention after a strong past 3 months, with a total return of about 31.9% and a 1 year total return of roughly 35.3%. That share move sits alongside reported annual revenue of US$609.3 million and net income of US$69.2 million, with both revenue and net income growth figures reported at 10.2% and 20.0% respectively. See our latest analysis for Vita Coco Company. Vita Coco’s share price has been choppy in the short term,...
NYSE:PBH
NYSE:PBHPharmaceuticals

The Bull Case For Prestige Consumer Healthcare (PBH) Could Change Following New TheraTears Digital-Eye Offerings

In January 2026, Prestige Consumer Healthcare’s TheraTears brand announced two new nationwide products, Eyelid Cleansing Wipes and Dry & Tired preservative-free lubricant eye drops, aimed at gentle daily lid care and relief from screen-related eye fatigue. The launches underscore how Prestige is tailoring its eye-care portfolio to everyday digital device use, with individually wrapped wipes and single-use vials designed for convenience and sensitive eyes. With these new TheraTears offerings...
NYSE:S
NYSE:SSoftware

SentinelOne’s Interim CFO Move Amid Guidance Scrutiny Might Change The Case For Investing In SentinelOne (S)

SentinelOne, Inc. recently confirmed that Chief Growth Officer Barry Padgett formally assumed the role of interim Chief Financial Officer and principal financial officer on January 16, 2026, following the previously announced resignation of CFO Barbara Larson. This leadership transition arrives after a period of investor unease around growth, guidance, and profitability, putting extra focus on how the finance function supports SentinelOne’s evolving business priorities. We’ll now examine how...
NasdaqGS:WSBC
NasdaqGS:WSBCBanks

Is WesBanco (WSBC) Pricing Reflect Its Recent Share Performance And Earnings Valuation Metrics

If you are wondering whether WesBanco's current share price offers good value or not, the key question is how that price compares with what the business might reasonably be worth. With the stock last closing at US$34.67 and returns of 0.8% over 7 days, 1.3% over 30 days, 4.0% year to date, 6.3% over 1 year, 11.0% over 3 years, and 49.0% over 5 years, many investors are asking whether the recent performance still leaves room for attractive value or instead signals a change in risk. Recent...
NYSE:HOMB
NYSE:HOMBBanks

A Look At Home Bancshares (HOMB) Valuation After Recent Share Price Softness

Recent performance snapshot for Home Bancshares stock Home Bancshares (HOMB) shares recently closed at $28.35, with a modest loss over the past year despite positive total returns over the past 3 years and 5 years, which may interest longer term investors. Shorter term moves have been mixed, with a 1 day return of about a 3.3% decline, a 7 day return of roughly a 2% decline, and a small loss over the past month. Over the past 3 months the shares show a mid single digit gain. In this context,...
NYSE:QTWO
NYSE:QTWOSoftware

A Look At Q2 Holdings (QTWO) Valuation After Earnings Beat And Raised EBITDA Guidance

Q2 Holdings (QTWO) is back in focus after quarterly results topped analyst estimates for revenue and EBITDA, and management raised full year EBITDA guidance, prompting investors to reassess the digital banking specialist’s stock. See our latest analysis for Q2 Holdings. The quarterly beat and guidance upgrade come after a mixed share price run. A 9.99% 90 day share price return contrasts with a 27.26% 1 year total shareholder return decline and a 108.65% 3 year total shareholder return gain,...
NasdaqGS:SDGR
NasdaqGS:SDGRHealthcare Services

Is Manas AI’s Platform Deal Reshaping the Investment Case For Schrödinger’s (SDGR) Drug Discovery Model?

In January 2026, Manas AI announced a multi-year agreement granting it extensive access to Schrödinger’s physics-based computational drug discovery platform and expert support, aimed at integrating this technology with its AI “world model” for identifying diverse molecular binders. A key angle for investors is that Schrödinger’s tools will be tightly embedded into Manas AI’s large-scale discovery workflows, potentially reinforcing Schrödinger’s position in AI-enabled molecular design...
NYSE:FDP
NYSE:FDPFood

Fresh Del Monte (FDP) Valuation Check As Sales Stagnation And Forecast Revenue Decline Raise New Questions

Why Fresh Del Monte Produce Is Back in Focus Fresh Del Monte Produce (FDP) is back on investors’ radar after reports of several years of stagnant sales and a forecasted 2.9% revenue decline, raising fresh questions about demand and the company’s growth options. See our latest analysis for Fresh Del Monte Produce. Against concerns about softer demand, Fresh Del Monte Produce’s share price has moved to $38.12, with a 30 day share price return of 5.98% and a 90 day gain of 10.91%. Its 1 year...
NasdaqGS:IBRX
NasdaqGS:IBRXBiotechs

Why ImmunityBio (IBRX) Is Up 16.8% After New ANKTIVA Data, FDA Progress And Saudi Approvals

In recent weeks, ImmunityBio has reported updated Phase 2 data in recurrent glioblastoma, advanced FDA discussions on its ANKTIVA bladder cancer filings, and secured Saudi approvals for ANKTIVA in both non-muscle invasive bladder cancer and metastatic non-small cell lung cancer. Together, these developments highlight ImmunityBio’s attempt to build a broad immunotherapy platform spanning checkpoint-experienced lung cancer, bladder cancer, and chemo-free cell therapy combinations in...
NasdaqGS:LOPE
NasdaqGS:LOPEConsumer Services

The Bull Case For Grand Canyon Education (LOPE) Could Change Following Conflicting Analyst And Investor Sentiment - Learn Why

In recent months, Barrington Research has repeatedly reaffirmed its “Outperform” rating on Grand Canyon Education, underscoring confidence in the company’s business performance amid sector headwinds and regulatory uncertainties. At the same time, Riverwater Partners highlighted Grand Canyon Education as a major short-term detractor while still describing it as a high-quality operator with resilient demand and strong returns on invested capital. Next, we’ll examine how this combination of...
NasdaqGM:ORKA
NasdaqGM:ORKABiotechs

How Early ORKA-002 Dosing Data At Oruka Therapeutics (ORKA) Has Changed Its Investment Story

Oruka Therapeutics, Inc. recently reported positive interim data from its first-in-human Phase 1 trial of ORKA-002, showing a long half-life, sustained IL-17 inhibition and a class-consistent safety profile in healthy volunteers, while outlining multiple ongoing and planned psoriasis and hidradenitis suppurativa studies across its ORKA-001 and ORKA-002 programs. A key insight for investors is the early clinical evidence suggesting ORKA-002 may enable twice-yearly maintenance dosing,...
NasdaqGS:EXPE
NasdaqGS:EXPEHospitality

A Look At Expedia Group (EXPE) Valuation After Analyst Upgrades And Tech Progress

Recent analyst commentary around Expedia Group (EXPE) has centered on rising confidence in its tech driven model, with upgraded stock recommendations and higher published targets following progress in B2B, the One Key rollout, and share buybacks. See our latest analysis for Expedia Group. At a share price of US$271.14, Expedia Group has seen a 23.89% 90 day share price return and a 59.63% 1 year total shareholder return, suggesting recent momentum after a softer past month. If this shift in...
NasdaqGS:UBSI
NasdaqGS:UBSIBanks

Did Earnings Beat, Buyback and Piedmont Deal Just Shift United Bankshares' (UBSI) Investment Narrative?

In late 2025 and early 2026, United Bankshares completed a US$27.37 million buyback of 700,000 shares, or about 0.5% of its stock, while reporting fourth-quarter 2025 earnings and revenue that exceeded Wall Street expectations and delivered strong year-on-year sales growth. The combination of record 2025 earnings, benefits from the Piedmont Bancorp acquisition, and active share repurchases underscored solid capital strength and cash generation alongside better-than-expected quarterly...
NasdaqGS:WAY
NasdaqGS:WAYHealthcare Services

Waystar Holding (WAY) Valuation Check After New Agentic Intelligence Capabilities For AltitudeAI Platform

Waystar Holding (WAY) has put its new agentic intelligence capabilities for its AltitudeAI platform in the spotlight, targeting more automated healthcare revenue workflows, just as it prepares for presentations at key industry conferences. See our latest analysis for Waystar Holding. Despite the recent product announcement and upcoming conference appearances, Waystar Holding's share price performance has been weak. The 30-day share price return shows a decline of 9.18%, the 90-day share price...
NYSE:ORA
NYSE:ORARenewable Energy

Ormat’s Sage Geosystems Deal and Indonesia Win Might Change The Case For Investing In ORA

In January 2026, Ormat Technologies announced a US$25 million equity investment in Sage Geosystems and a long-term geothermal power purchase agreement with Switch, alongside securing Indonesia’s Telaga Ranu Geothermal Working Area concession. Together, these moves expand Ormat’s access to next-generation geothermal technology, deepen its role in data center decarbonization, and extend its project pipeline in Indonesia’s energy transition program. We’ll now examine how Ormat’s collaboration...
NYSE:LMND
NYSE:LMNDInsurance

Lemonade’s FSD Insurance Launch Prompts Fresh Look At Valuation And Growth Expectations

How Lemonade’s FSD Product Could Matter for Investors Lemonade (LMND) is putting its data centric model to the test with Lemonade Autonomous Car insurance, a new product for Tesla Full Self Driving that cuts per mile rates by about 50% when FSD is engaged. For you as an investor, the key questions are how this first of its kind product, backed by Tesla vehicle data and rolling out initially in Arizona and Oregon, might influence Lemonade’s growth profile, risk exposure, and long term...
NasdaqGS:PLMR
NasdaqGS:PLMRInsurance

Is It Too Late To Revisit Palomar Holdings (PLMR) After Its Strong Multi‑Year Rally?

If you are wondering whether Palomar Holdings at around US$124.95 is still a sensible entry or hold after a strong run, the key question is how that price stacks up against its underlying value. The stock has seen a 20.7% return over the last year and a very large 3 year return, even though the shorter term picture shows a 2.7% decline over 7 days, an 8.1% decline over 30 days, and a 5.2% decline year to date. Recent attention on the stock has focused on its position in the insurance sector...